urea has been researched along with Amentia in 19 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 9.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "We report a successful case of sedation during spinal anesthesia using continuous administration of landiolol and dexmedetomidine in a patient with severe dementia." | 7.81 | [Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia]. ( Deguchi, S; Fujiwara, S; Kido, H; Komasawa, N; Minami, T, 2015) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 6.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 6.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 5.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| " Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia." | 4.31 | Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. ( Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H, 2023) |
| "Active cancer, dementia, and high values for urea and RDW at admission are predictors of one-year mortality in patients hospitalized for HF." | 4.31 | One-year mortality after hospitalization for acute heart failure: Predicting factors (PRECIC study subanalysis). ( Lopes Ramos, R; Marques, I; Mendonça, D; Teixeira, L, 2023) |
| "We report a successful case of sedation during spinal anesthesia using continuous administration of landiolol and dexmedetomidine in a patient with severe dementia." | 3.81 | [Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia]. ( Deguchi, S; Fujiwara, S; Kido, H; Komasawa, N; Minami, T, 2015) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 2.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 2.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality." | 2.46 | Parkinson's disease dementia. ( Burn, DJ; Docherty, MJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Tariot, PN | 2 |
| Ballard, C | 3 |
| Devanand, DP | 3 |
| Cummings, JL | 3 |
| Sultzer, DL | 2 |
| Schneider, LS | 1 |
| Longardner, K | 1 |
| Wright, BA | 1 |
| Alakkas, A | 1 |
| You, H | 1 |
| Xu, R | 1 |
| Liu, L | 1 |
| Nahab, FB | 1 |
| Marques, I | 1 |
| Lopes Ramos, R | 1 |
| Mendonça, D | 1 |
| Teixeira, L | 1 |
| Stahl, SM | 1 |
| Soto-Martin, ME | 1 |
| Erten-Lyons, D | 1 |
| Weintraub, D | 1 |
| McEvoy, B | 1 |
| Youakim, JM | 1 |
| Stankovic, S | 2 |
| Foff, EP | 1 |
| Friedman, JI | 1 |
| Liu, KY | 1 |
| Howard, R | 1 |
| Cummings, J | 1 |
| Tariot, P | 1 |
| Owen, R | 1 |
| Foff, E | 1 |
| Youakim, J | 1 |
| Norton, J | 1 |
| Deguchi, S | 1 |
| Komasawa, N | 1 |
| Fujiwara, S | 1 |
| Kido, H | 1 |
| Minami, T | 1 |
| Docherty, MJ | 1 |
| Burn, DJ | 1 |
| Belorgey, D | 1 |
| Sharp, LK | 1 |
| Crowther, DC | 1 |
| Onda, M | 1 |
| Johansson, J | 1 |
| Lomas, DA | 1 |
| Selkoe, DJ | 1 |
| Ihara, Y | 1 |
| Salazar, FJ | 1 |
| Anderton, B | 1 |
| Tokutake, S | 1 |
| Oyanagi, S | 1 |
| Itil, TM | 1 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Murray, RM | 1 |
| Greene, JG | 1 |
| Adams, JH | 1 |
| Hsia, YE | 1 |
| Thomas, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis[NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The endpoint of time from randomization to discontinuation from the DB period for any reason (other than termination of the study by the sponsor) was compared between treatment groups using a Cox regression model. The treatment effect was measured by the HR. (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
"The time from randomization to relapse in the DB period was compared between treatment groups using a Cox regression model. The treatment effect was measured by the hazard ratio (HR).~Relapse was defined as (1) ≥30% increase in SAPS-H+D total score from DB baseline (BL) and CGI-I score ≥6 relative to DB BL, (2) treatment with antipsychotic for dementia-related delusions/hallucinations, (3) treatment/study discontinuation due to lack of efficacy, and/or (4) hospitalization for worsening dementia-related psychosis.~SAPS-H+D is a 20-item scale; the total score is the sum of the 20 item scores (range 0-100); higher scores denote more severe symptoms. CGI-I is a clinician-rated 7-point scale to rate improvement in hallucinations/delusions relative to BL (range 1-7); higher scores denote less improvement or worsening.~A pre-specified IA was conducted after accrual of 40 adjudicated relapse events. The prespecified stopping criterion was met; the study was stopped for efficacy." (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
4 reviews available for urea and Amentia
| Article | Year |
|---|---|
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Par | 2018 |
Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Diagnosis, Differential; Humans; Park | 2010 |
Inherited hyperammonemic syndromes.
Topics: Acidosis; Amino Acids; Ammonia; Animals; Arginine; Brain; Brain Diseases; Chemical and Drug Induced | 1974 |
2 trials available for urea and Amentia
| Article | Year |
|---|---|
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations | 2021 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
13 other studies available for urea and Amentia
| Article | Year |
|---|---|
Pimavanserin and dementia-related psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psyc | 2023 |
One-year mortality after hospitalization for acute heart failure: Predicting factors (PRECIC study subanalysis).
Topics: Aged; Aged, 80 and over; Dementia; Erythrocyte Indices; Heart Failure; Hospitalization; Humans; Prog | 2023 |
Pimavanserin in Dementia-Related Psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Topics: Clinical Trials as Topic; Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
[Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia].
Topics: Aged, 80 and over; Anesthesia, Spinal; Dementia; Dexmedetomidine; Femoral Fractures; Humans; Hypnoti | 2015 |
Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB.
Topics: Amino Acid Substitution; Arginine; Biopolymers; Catalysis; Circular Dichroism; Dementia; Epilepsy; H | 2004 |
Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea.
Topics: Alzheimer Disease; Cerebral Cortex; Cytoskeleton; Dementia; gamma-Glutamyltransferase; Humans; Micro | 1982 |
Untangling insoluble filaments.
Topics: Acyltransferases; Alzheimer Disease; Dementia; Guanidine; Guanidines; Humans; Neurofibrils; Octoxyno | 1983 |
Mechanical instability of Pick bodies and their isolation in an intact form using urea solution.
Topics: Brain; Dementia; Female; Hematoxylin; Humans; Inclusion Bodies; Microscopy, Electron; Middle Aged; N | 1993 |
Analgesics abuse and dementia.
Topics: Aged; Analgesics; Aspirin; Brain; Dementia; Female; Humans; Intelligence Tests; Male; Middle Aged; P | 1971 |
Values of serum iron in patients over sixty.
Topics: Aged; Anemia, Hypochromic; Anemia, Pernicious; Arthritis, Rheumatoid; Circadian Rhythm; Dementia; Fe | 1971 |